Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions.
With the expanding use of endovascular techniques for the treatment of peripheral vascular disease, consideration of glycoprotein IIb/IIIa receptor inhibitors to enhance the safety and efficacy of these procedures has increased. The scientific literature shows the benefits with the use of these agents in coronary vasculature interventions. However, data evaluating treatment with glycoprotein IIb/IIIa receptor inhibitors during peripheral vascular procedures is limited, with the vast majority of the trials investigating abciximab. With the varied vascular beds and end organs that may be affected by peripheral vascular intervention, the safety and efficacy may need to be studies for each area. The current literature ranging from carotid stenting to thrombolysis and mechanical thrombectomy for acute limb ischemia is reviewed, and recommendations are discussed on the use of these agents. The forthcoming results of controlled clinical trials should further clarify the clinical applications of these agents in peripheral vascular intervention.
Ansel
Gary M
GM
MidOhio Cardiology and Vascular Consultants, Columbus, Ohio, USA.
George
Barry S
BS
Botti
Charles F
CF
Silver
Mitchell J
MJ
D006801:Humans; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures
D019039:Platelet Glycoprotein GPIIb-IIIa Complex